Comparative safety of denosumab and romosozumab in osteoporosis: an analysis based on the FDA adverse event reporting system database
Research based on FAERS revealed distinct differences in the safety profiles of denosumab and romosozumab. Clinical decision makers should deepen their understanding of these features to advance personalized therapy and improve medication safety.
Authors
- Sun Jw
- Jin Li (ORCID: https://orcid.org/0000-0002-6131-456X)
- Yao Wu
- Ciren Lunzhu
Institutions
- Anhui Medical University (CN)
- Shatin Hospital (CN)
- Anhui Provincial Hospital (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-02-05
- DOI
- https://doi.org/10.3389/fmed.2026.1766601
- Primary Topic
- Bone Metabolism and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Anhui Medical University